Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [7][9]. Core Insights - The company's wholesale business is gradually recovering in Q3, with a projected stable growth outlook for the coming year. The total revenue for the first three quarters of 2025 was 15.758 billion yuan, a decrease of 1.47% year-on-year, while the net profit attributable to shareholders was 646 million yuan, down 9.81% [3][4]. - The decline in revenue and profit is primarily attributed to the impact of centralized procurement policies and hospital drug sales control, which have led to a temporary decrease in sales volume and profit margins in the wholesale segment. However, improvements in product structure and cost reduction efforts are expected to support a gradual recovery in performance [4][5]. - The retail and industrial segments showed steady growth, with retail revenue increasing by 8.17% to 2.591 billion yuan and industrial revenue rising by 6.44% to 860 million yuan in the first three quarters of 2025 [5]. Financial Performance Summary - For Q1-Q3 2025, the gross margin was 10.88%, a decrease of 0.88 percentage points, while the net profit margin was 4.10%, down 0.38 percentage points. The company’s operating cash flow net amount was 135 million yuan, an increase of 10.09% [4]. - The company’s revenue projections for 2025-2027 are 21.133 billion yuan, 22.221 billion yuan, and 23.383 billion yuan, respectively, with net profits expected to be 828 million yuan, 873 million yuan, and 922 million yuan [9][11]. Strategic Initiatives - The company has implemented an employee stock ownership plan and stock option incentive plan to enhance talent retention and core team cohesion. The first transfer of shares under the employee stock ownership plan has been completed, involving 52 employees [6]. - To diversify its product offerings and enhance competitiveness, the company has established a wholly-owned subsidiary and signed an investment agreement with Suninflam Ltd. for the development of an innovative monoclonal antibody drug targeting inflammation-related factors in epilepsy [8].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [7][9]. Core Insights - The company is experiencing temporary performance pressure due to delayed implementation of centralized procurement and internal channel restructuring. For the first three quarters of 2025, the company reported revenue of 4.751 billion yuan, a decrease of 18.08%, and a net profit attributable to shareholders of 269 million yuan, down 39.42% [3][4]. - The company is undergoing significant internal reforms, including channel restructuring and model transformation, which are expected to gradually improve business performance as new products are launched and centralized procurement progresses [3][5]. Financial Performance - For the first three quarters of 2025, the gross margin was 39.42%, down 4.40 percentage points, and the net profit margin was 5.67%, down 2.00 percentage points. The company’s operating cash flow net amount was 176 million yuan, a decrease of 52.43% [4]. - The company’s revenue projections for 2025-2027 are 8.247 billion yuan, 9.007 billion yuan, and 9.839 billion yuan, respectively, with net profits of 599 million yuan, 709 million yuan, and 851 million yuan, corresponding to price-to-earnings ratios of 16, 14, and 12 times [9][11]. Business Development - The company is enhancing its channel coverage through the integration of its 777 division with Huaren Shenghuo, focusing on the dual promotion of its blood circulation products. It is also expanding its overseas market presence, particularly in Indonesia, to leverage local clinical research and academic exchanges [5][6]. - Ongoing research projects include a new drug for treating ischemic stroke and several other drugs in various stages of clinical trials, indicating a robust pipeline for future growth [6].

1. Report Industry Investment Rating There is no information provided regarding the report's industry investment rating in the given content. 2. Core Views of the Report - Residents' investment preference is rising, but there is still a demand for safe assets. They show a contradiction of "declining risk preference but still having a desire for returns" [3]. - The scale of wealth management products is expected to continue growing, but their yields still face challenges. In the context of deposit disintermediation, there is still room for growth in the scale of wealth management in 2026 [4]. - Public - offering bond funds and wealth management are interacting more deeply. Attention should be paid to the changing trends in product structure. The public - offering bond fund market is undergoing a pattern reshaping [5]. 3. Summary According to the Directory 3.1 Liability Side: Residents' Investment Preference Rises, and the Demand for Safe Assets Remains - **Limited Asset Allocation Options and Sustained Demand for Safe Assets**: Residents' asset allocation shows a contradiction between balancing safety and returns. They have a reduced risk - bearing capacity on the asset side and a demand for "elastic returns" in low - risk assets [11][13]. - **Strengthened Deposit Disintermediation and Changed Investment Will**: Deposit rate cuts have strengthened the deposit disintermediation trend. The improvement of the equity market has made residents more willing to invest, and they prefer fund trusts over stocks [16][18]. 3.2 Wealth Management Products: Scale Expected to Continue Growing, Yields Still Facing Challenges - **Wealth Management Scale: Returned Above 30 Trillion, Investment Returns Under Pressure**: In Q3 2025, the bank wealth management scale reached 32.13 trillion yuan. The number of products increased steadily, with fixed - income products dominating. The number of participants also continued to grow. However, the yields of underlying assets of wealth management products have declined [19][24]. - **Wealth Management Behavior: Strategies for Stable Scale and Reduced Volatility**: To achieve stable scale and reduced volatility, wealth management has adjusted its asset allocation. It has increased the proportion of cash and deposits and changed its bond investment preferences, such as increasing the preference for inter - bank certificates of deposit and avoiding corporate bonds [26][29]. - **Regulatory Environment: Systemic Tightening Continues, a Major Source of Risk**: The regulatory environment for wealth management is tightening. Net - value reform and regulatory policies such as the "Asset Management Trust New Regulations" may affect the underlying assets of wealth management products. In the future, wealth management will focus more on high - liquidity assets [32][34]. 3.3 Public - Offering Bond Funds: Deep Interaction with Wealth Management, Focus on Product Structure Changes - **Public - Offering Scale Keeps Growing, Bond Fund Redemption Pressure Emerges**: As of the end of November 2025, the total scale of public - offering funds exceeded 36 trillion yuan. The combined proportion of bond funds and money market funds decreased compared to the end of 2024. The scale of bond funds fluctuated upward, but they faced redemption pressure [38]. - **During the Concentrated Opening Period of Fixed - Open Funds, Wealth Management Takes Over as the Main Allocator**: From December 2025 to May 2026, fixed - open bond funds will have a concentrated opening period. Wealth management is likely to increase its allocation of credit - type coupon assets through these funds and reduce the allocation of interest - rate products such as policy - financial bonds [42][45]. - **Expansion of ETF Bond Funds, Growing Interest from Wealth Management**: In 2025, the scale of bond ETFs expanded significantly. Wealth management products may become an important force in bond ETF allocation. In the future, the public - offering bond fund market will undergo a pattern reshaping [46][52].

发布时间：2025-12-11 证券研究报告：宏观报告 研究所 分析师:袁野 SAC 登记编号:S1340523010002 Email:yuanye@cnpsec.com 研究助理:苑西恒 SAC 登记编号:S1340124020005 Email:yuanxiheng@cnpsec.com 近期研究报告 《全球流动性处于何种水平？---数量 篇》 - 2025.12.8 宏观研究 目录 鲜菜鲜果涨价支撑食品改善，服务价格相对稳固 核心观点 CPI 同比增速连续三个月呈现修复态势，虽然存在基数走低的影 响，但剔除基数效应，从两年复合增速来看，CPI 同比增速仍呈现边 际改善。（1）从结构来看，食品项价格边际改善明显，成为当月 CPI 价格改善的主要原因，其中，鲜菜和鲜果是主要贡献，两个分项对当 月食品项价格同比增速改善贡献度达到 54.29%，背后是低温阴雨+冷 冻灾害影响，短期供应不足，推升价格上涨，与此同时，因牛羊存栏 量下滑，出栏供给偏紧，2025 年下半年供给进入收缩通道，牛羊肉价 格同比增速保持稳定上涨；（2）从非食品分项价格来看，服务消费价 格保持相对坚挺，如教育文化和娱乐、医疗保健、家庭服务、 ...

Export Performance - In November, China's export growth exceeded expectations, with a year-on-year increase of 5.9%, up 7 percentage points from the previous value[9] - The two-year compound growth rate for exports in November was 6.24%, an increase of 0.69 percentage points compared to the previous value, and better than the Wind consensus estimate of 2.94%[9] - Exports to the EU, Japan, and South Korea were the main contributors to the growth, while exports to the US continued to weaken[10] Key Trade Partners - Exports to the EU grew by 14.83% in November, a significant increase of 13.9 percentage points from the previous value, driven by low base effects and competitive pricing[12] - Exports to Japan increased by 4.3%, up 10.01 percentage points, attributed to Japan's high inflation and competitive pricing of Chinese goods[15] - Exports to South Korea rose by 1.92%, a recovery of 14.97 percentage points, influenced by low base effects and competitive pricing[15] Key Products - High-tech products and machinery exports maintained strong growth, with high-tech products growing by 7.68% and machinery products by 9.65%[18] - Key items such as automobiles, integrated circuits, and LCD modules saw significant export growth rates of 52.97%, 34.17%, and 17.57% respectively[18] Import Performance - In November, China's import growth was 1.9%, which was below market expectations of 2.85% but better than the five-year historical average by 4.28 percentage points[19] - Imports from the EU, Japan, and South Korea showed positive contributions, with respective contributions of 0.16%, 0.44%, and 0.47% to the overall import growth[22] Future Outlook - The report maintains that exports will remain a significant contributor to economic growth, with an expected growth rate of around 2% in 2026[3] - The ongoing strengthening of China-EU cooperation is expected to continue, driven by trade transfer effects amid global trade restructuring[24] - Despite uncertainties in US-China trade relations, stability is anticipated following multiple rounds of negotiations[24]

| 最新收盘价（元） | 31.98 | | --- | --- | | 总股本/流通股本（亿股）4.10 | / 4.10 | | 总市值/流通市值（亿元）131 | / 131 | | 52 周内最高/最低价 | 40.79 / 24.06 | | 资产负债率(%) | 70.4% | | 市盈率 | 199.88 | | 第一大股东 | 浙江甬顺芯电子有限公 | | 司 | | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 分析师:翟一梦 SAC 登记编号:S1340525040003 Email:zhaiyimeng@cnpsec.com 甬矽电子(688362) 证券研究报告：电子 | 公司点评报告 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 消费类订单持续饱满，2.5D 封装加速验证 l 投资要点 消费类订单持续饱满。2025 年前三季度，随着全球终端消费 市场持续回暖，产业链去库存周期基本结束，叠加 AI 应用场景不 断涌现，集成电路行业整体景气度维持在较高水平。2025 年前三 季度，得益于海外大客户的 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 20% relative to the benchmark index within the next six months [9][15]. Core Insights - The company reported a revenue of 215.07 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 2.60%. The pharmaceutical industrial segment saw a slight decline in sales revenue by 0.66%, while the pharmaceutical commercial segment grew by 2.91% [3][4]. - The net profit attributable to the parent company for the same period was 5.147 billion yuan, an increase of 26.96%. However, the non-recurring net profit decreased by 26.79% to 2.699 billion yuan [3][4]. - The company’s innovative drug business achieved sales revenue of 40.7 billion yuan, growing over 25% year-on-year, indicating strong growth in this segment [5]. Financial Performance Summary - For Q1-Q3 2025, the company’s gross margin was 10.42%, a decrease of 0.63 percentage points, while the net profit margin increased by 0.46 percentage points to 2.39% [4]. - The company’s R&D investment for the first nine months of 2025 was 1.729 billion yuan, accounting for 9.52% of the pharmaceutical industrial sales revenue [6]. - The forecasted revenues for 2025, 2026, and 2027 are 286.67 billion yuan, 301.44 billion yuan, and 317.14 billion yuan, respectively, with net profits expected to be 5.701 billion yuan, 5.538 billion yuan, and 6.074 billion yuan [9][11].

证券研究报告：电子 | 公司点评报告 股票投资评级 公司基本情况 | 最新收盘价（元） | 457.46 | | --- | --- | | 总股本/流通股本（亿股）7.24 | / 7.24 | | 总市值/流通市值（亿元）3,314 | / 3,312 | | 52 周内最高/最低价 | 468.00 / 318.60 | | 资产负债率(%) | 51.0% | | 市盈率 | 43.27 | | 第一大股东 | 北京七星华电科技集团 | | 有限责任公司 | | 研究所 受益于晶圆厂区域化趋势以及数据中心和边缘设备中 AI 芯片需求 激增，SEMI 预计 2025 年全球 300mm 晶圆厂设备支出将首次超过 1,000 亿美元，增长 7%至 1,070 亿美元；2026 年将增长 9%，达到 1,160 亿美元；2027 年增长 4%，达到 1,200 亿美元；2028 年将增 长 15%，达到 1,380 亿美元；其中中国大陆预计将继续领先全球 300mm 设备支出，2026 至 2028 年间投资总额将达 940 亿美元。全 球分领域看，Logic 和 Micro 领域预计将在 2026 至 2 ...

证券研究报告：医药生物 | 公司点评报告 发布时间：2025-12-11 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 17.44 | | --- | --- | | 总股本/流通股本（亿股）11.39 | / 11.39 | | 总市值/流通市值（亿元）199 | / 199 | | 周内最高/最低价 52 | 19.41 / 13.57 | | 资产负债率(%) | 69.2% | | 市盈率 | 21.53 | | 第一大股东 | 柯云峰 | 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:龙永茂 SAC 登记编号:S1340523110002 Email:longyongmao@cnpsec.com 大参林(603233) Q3 业绩高速增长，经营质量持续提升 l 业绩环比提速增长，盈利能力持续提升 公司发布 2025 年三季报：2025Q1-3 公司实现营业收入 200.68 亿 元（+1.71%），归母净利润 10.81 亿元（+25.97%），扣非净利润 10.73 亿 ...

证券研究报告：电子 | 公司点评报告 股票投资评级 买入 |维持 个股表现 2024-12 2025-02 2025-05 2025-07 2025-09 2025-12 -30% -22% -14% -6% 2% 10% 18% 26% 34% 42% 50% 芯联集成 电子 资料来源：聚源，中邮证券研究所 公司基本情况 l 投资建议： 我们预计公司 2025/2026/2027 年营收分别为 81.0/101.0/126.6 亿元，归母净利润分别为-6.1/0.5/6.0 亿元，维持"买入"评级。 | 最新收盘价（元） | 6.46 | | --- | --- | | 总股本/流通股本（亿股）83.83 | / 44.30 | | 总市值/流通市值（亿元）542 | / 286 | | 52 周内最高/最低价 | 7.34 / 4.17 | | 资产负债率(%) | 41.7% | | 市盈率 | -46.14 | | 绍兴市越城区集成电路 | | | 第一大股东 | 产业基金合伙企业(有 | | 限合伙) | | 研究所 分析师:万玮 SAC 登记编号:S1340525030001 Email:wanw ...